Barclays raised the firm’s price target on Elevance Health (ELV) to $522 from $512 and keeps an Overweight rating on the shares following the Q1 report.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health Reports Strong Q1 2025 Results
- Elevance Health Q1 2025 Earnings Call Highlights
- Morning Movers: Danaher gains and Northrop Grumman sinks after earnings
- Elevance Health reports Q1 adjusted EPS $11.97, consensus $11.48
- Elevance Health backs FY25 adjusted EPS view of $34.15-$34.85, consensus $34.19
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue